M.T. Almodovar
M.T. Almodovar
*This is an algorithmically generated author record based on publicly available information.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
M.T. Almodovar has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Bárbara Parente
Assistente Hospitalar Sénior de Pneumologia, Centro Hospitalar Gaia/Espinho, Portugal
1 shared publication - Encarnação Teixeira
Hospital Pulido Valente, Centro Hospitalar Universitário Lisboa Norte
1 shared publication - Fernando Barata
Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
1 shared publication - Henrique Queiroga
Pulmonology Department, Centro Hospitalar Universitário São João; Faculty of Medicine, University of Porto, Porto, Portugal
1 shared publication - Marta Soares
Department of Medical Oncology, Portuguese Oncology Institute of Porto (IPO-Porto), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal
1 shared publication
Latest Publications
- Open Access
- 30 September 2016
- Published by Taylor & Francis in Revista Portuguesa de Pneumologia (English Edition)
- Vol. 22 (5) , 287-288
MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut+
- 30 September 2016
- Published by Taylor & Francis in Revista Portuguesa de Pneumologia (English Edition)
- Vol. 22 (5) , 287-288
Open AccessMuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut+